Is there a medication to thicken eyelashes?
Answer From Alaina L. Softing Hataye, O.D.
Yes. The medication bimatoprost — marketed under the brand name Latisse — is approved by the Food and Drug Administration (FDA) to treat inadequate eyelashes (hypotrichosis). Bimatoprost is also marketed under the brand name Lumigan, which is used in prescription eyedrops to treat glaucoma. Eyelash growth was an unexpected side effect of Lumigan, which led to the creation and marketing of Latisse.
With regular applications along the lash line of the upper eyelid, Latisse gradually encourages growth of longer, thicker and darker eyelashes. Latisse isn't meant to be applied to the lower eyelid. For full results, you must use the medication daily for at least two months. Eyelash improvements remain as long as you continue to use the medication. When you stop using Latisse, your eyelashes will eventually return to their original appearance.
Potential side effects of Latisse include:
- Redness of the thin tissue over the white part of the eye (conjunctiva)
- Itchy, red eyes
- Dry eyes
- Darkened eyelids
- Darkened brown pigmentation in the colored part of the eye (iris)
- Hair growth around the eyes if the medication regularly runs or drips off the eyelids
Although darkened eyelids might fade when the medication is stopped, any changes in iris color are likely to be permanent.
The results of studies of people who used Latisse for eyelash loss due to a medical condition that causes hair loss (alopecia areata) were mixed. Studies of people who have eyelash loss due to chemotherapy were more promising. Further studies are needed.
If you're concerned about the appearance of your eyelashes, talk to your doctor. He or she can help you weigh the pros and cons of using an eyelash-growing medication.
Alaina L. Softing Hataye, O.D.
May 06, 2020
Get the latest health information from Mayo Clinic’s experts.
Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID-19, plus expertise on managing health.
ErrorEmail field is required
ErrorInclude a valid email address
To provide you with the most relevant and helpful information, and understand which
information is beneficial, we may combine your email and website usage information with
other information we have about you. If you are a Mayo Clinic patient, this could
include protected health information. If we combine this information with your protected
health information, we will treat all of that information as protected health
information and will only use or disclose that information as set forth in our notice of
privacy practices. You may opt-out of email communications at any time by clicking on
the unsubscribe link in the e-mail.
Thank you for subscribing
Our Housecall e-newsletter will keep you up-to-date on the latest health information.
Sorry something went wrong with your subscription
Please, try again in a couple of minutes
See more Expert Answers
- Latisse (prescribing information). Irvine, Calif.: Allergan, Inc.; 2017. http://www.latisse.com/. Accessed March 8, 2018.
- Latisse: Real questions, real answers. Latisse. http://www.latisse.com/FAQs.aspx. Accessed March 8, 2018.
- Messenger AG. Management of alopecia areata. https://uptodate.com/contents/search. Accessed March 8, 2018.
- Spano F, et al. Alopecia areata, Part 2: Treatment. Canadian Family Physician. 2015;61:757.
- Glaser DA, et al. Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: A randomized controlled study. British Journal of Dermatology. 2015;172:1384.
- Bochert M, et al. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clinical Ophthalmology. 2016;10:419.